MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00520-022-06839-4

Медицинская библиотека · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022

Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.

Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y

Перевод в очереди

Аннотация

PURPOSE: Survival time after bisphosphonate use has been increasingly recognized to be associated with the incidence of medication-related osteonecrosis of the jaw (MRONJ); however, this has not been elucidated sufficiently in the literature. This study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid (ZA) for each type of cancer and obtain useful information for the oral/dental supportive care of cancer patients.

METHODS

We evaluated 988 patients who were administered ZA at our hospital; among them, 862 patients with metastatic bone tumors or myeloma were included.

RESULTS

The median survival time (MST) after ZA initiation was 35, 34, 8, 41, 12, and 6 months for patients with breast, prostrate, lung, myeloma, renal, and other cancers, respectively. Patients with cancers that had a short survival time (lung and other cancers [MST = 8 and 6 months, respectively] and cancers with MST < 10 months) did not develop MRONJ; this could be attributed to the shorter duration of ZA administration. The cumulative incidence of MRONJ in breast cancer, prostate cancer, and multiple myeloma was related to the frequency of anti-resorptive drug use and the increased risk over time. In renal cancer, the cumulative incidence of MRONJ increased early, although the MST was 12 months.

CONCLUSION

For the dentists in charge of dental management, it is essential to be aware of prognosis-related factors, predict MRONJ risk for each cancer treatment, and use risk prediction in dental management planning, particularly for cancers with non-poor prognosis.

Для цитирования: Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2022. DOI: 10.1007/s00520-022-06839-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.